Skip to main content
Top
Published in: Journal of Translational Medicine 1/2013

Open Access 01-12-2013 | Research

Gadd45a levels in human breast cancer are hormone receptor dependent

Authors: Jennifer S Tront, Alliric Willis, Yajue Huang, Barbara Hoffman, Dan A Liebermann

Published in: Journal of Translational Medicine | Issue 1/2013

Login to get access

Abstract

Background

Gadd45a is a member of the Gadd45 family of genes that are known stress sensors. Gadd45a has been shown to serve as an effector in oncogenic stress in breast carcinogenesis in murine models. The present study was aimed at clarifying the expression of Gadd45a in human breast cancer and its correlation with clinicopathologic features.

Methods

The expression levels of Gadd45a in breast tissue samples of female breast surgery cases were examined by immunohistochemistry (IHC) using a Gadd45a antibody. Percent staining was determined and statistical analyses were applied to determine prognostic correlations.

Results

56 female breast surgery cases were studied: Normal (11), Luminal A (9), Luminal B (11), HER2+ (10), Triple Negative (15). There was a highly significant difference in percent Gadd45a staining between groups [Mean]: Normal 16.3%; Luminal A 65.3%; Luminal B 80.7%; HER2+ 40.5%; TN 32%, P < 0.001, ANOVA. Gadd45a IHC levels for Normal cases found 82% negative/low. Luminal A breast cancer cases were found to be 67% high. Luminal B breast cancers were 100% high. Her2+ cases were 50% negative/low. Triple Negative cases were 67% negative/low. This difference in distribution of Gadd45a levels across breast cancer receptor subtypes was significant, P = 0.0009.

Conclusions

Gadd45a levels are significantly associated with hormone receptor status in human breast cancer. Normal breast tissue displays low Gadd45a levels. High Gadd45a levels are associated with Luminal A and Luminal B subtypes. Absence of hormone receptors in Triple Negative subtype is associated with Negative/Low levels of Gadd45a. Further studies are indicated to elucidate the role of Gadd45a in breast cancer as a potential prognosticator or target for treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference U.S. Cancer Statistics Working Group: United States Cancer Statistics: 1999–2008 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute. 2012, Available at: http://www.cdc.gov/uscs U.S. Cancer Statistics Working Group: United States Cancer Statistics: 1999–2008 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute. 2012, Available at: http://​www.​cdc.​gov/​uscs
2.
go back to reference American Cancer Society: Cancer Facts and Figures 2012. 2012, Atlanta, GA: American Cancer Society American Cancer Society: Cancer Facts and Figures 2012. 2012, Atlanta, GA: American Cancer Society
3.
go back to reference Greene MI: Breast cancer genes. Oncogene Reviews. 2000, 19: 2984-2989. Greene MI: Breast cancer genes. Oncogene Reviews. 2000, 19: 2984-2989.
4.
go back to reference Cretu A, Sha X, Tront J, Hoffman B, Liebermann DA: Stress sensor Gadd45 genes as therapeutic targets in cancer. Cancer Ther. 2009, 7 (A): 268-276.PubMedCentralPubMed Cretu A, Sha X, Tront J, Hoffman B, Liebermann DA: Stress sensor Gadd45 genes as therapeutic targets in cancer. Cancer Ther. 2009, 7 (A): 268-276.PubMedCentralPubMed
5.
go back to reference Liebermann D, Hoffman B: MyD genes in negative growth control. Oncogene Reviews. 1998, 17: 3319-3330.CrossRef Liebermann D, Hoffman B: MyD genes in negative growth control. Oncogene Reviews. 1998, 17: 3319-3330.CrossRef
6.
go back to reference Fornace A, Jackman J, Hollander M, Hoffman-Liebermann B, Liebermann D: Genotoxic stress response genes and growth arrest genes: gadd, MyD and other genes induced by treatments eliciting growth arrest. Ann NY Acad Of Sci. 1992, 663: 139-154. 10.1111/j.1749-6632.1992.tb38657.x.CrossRef Fornace A, Jackman J, Hollander M, Hoffman-Liebermann B, Liebermann D: Genotoxic stress response genes and growth arrest genes: gadd, MyD and other genes induced by treatments eliciting growth arrest. Ann NY Acad Of Sci. 1992, 663: 139-154. 10.1111/j.1749-6632.1992.tb38657.x.CrossRef
7.
go back to reference Carrier F, Georgel P, Pourquier P, Blake M, Kontny H, Antinore M: Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin. MCB. 1999, 19: 1673-1685.PubMedCentralCrossRefPubMed Carrier F, Georgel P, Pourquier P, Blake M, Kontny H, Antinore M: Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin. MCB. 1999, 19: 1673-1685.PubMedCentralCrossRefPubMed
8.
go back to reference Miki Y, Swensen J, Shattuck-Eidens J, Futreal P, Harshman K, Tavtigian S: A strong candidate for the breast and ovarian susceptibility gene BRCA1. Science. 1994, 266: 66-10.1126/science.7545954.CrossRefPubMed Miki Y, Swensen J, Shattuck-Eidens J, Futreal P, Harshman K, Tavtigian S: A strong candidate for the breast and ovarian susceptibility gene BRCA1. Science. 1994, 266: 66-10.1126/science.7545954.CrossRefPubMed
9.
go back to reference Tront J, Hoffman B, Liebermann D: Gadd45a suppresses ras-driven mammary tumorigenesis by activation of Jnk and p38 stress signaling resulting in apoptosis and senescence. Cancer Res. 2006, 17: 8448-8454.CrossRef Tront J, Hoffman B, Liebermann D: Gadd45a suppresses ras-driven mammary tumorigenesis by activation of Jnk and p38 stress signaling resulting in apoptosis and senescence. Cancer Res. 2006, 17: 8448-8454.CrossRef
10.
go back to reference Tront J, Hoffman B, Liebermann D: Gadd45a functions as a promoter or suppressor of breast cancer dependent on the oncogenic stress. Cancer Res. 2010, 70: 9671-9681. 10.1158/0008-5472.CAN-10-2177.PubMedCentralCrossRefPubMed Tront J, Hoffman B, Liebermann D: Gadd45a functions as a promoter or suppressor of breast cancer dependent on the oncogenic stress. Cancer Res. 2010, 70: 9671-9681. 10.1158/0008-5472.CAN-10-2177.PubMedCentralCrossRefPubMed
11.
go back to reference Lakhani S, Ellis I, Schnitt S, Tan P, van de Vijver MJ: Pathology and Genetics Tumours of the Breast and Female Genital Organs. 2012, Lyon, France: IARC WHO Classification of Tumours, No 4 Ed. IARC Press Lakhani S, Ellis I, Schnitt S, Tan P, van de Vijver MJ: Pathology and Genetics Tumours of the Breast and Female Genital Organs. 2012, Lyon, France: IARC WHO Classification of Tumours, No 4 Ed. IARC Press
12.
go back to reference AJCC Cancer Staging Manual 7th Ed. Edited by: Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A. 2010, New York: Springer AJCC Cancer Staging Manual 7th Ed. Edited by: Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A. 2010, New York: Springer
Metadata
Title
Gadd45a levels in human breast cancer are hormone receptor dependent
Authors
Jennifer S Tront
Alliric Willis
Yajue Huang
Barbara Hoffman
Dan A Liebermann
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2013
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-11-131

Other articles of this Issue 1/2013

Journal of Translational Medicine 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine